The pharmaceutical industry has always lived with a productive tension. It is one of the most innovative sectors in the world, yet it operates under constraints that few other industries face - scientific uncertainty, long development timelines, manufacturing complexity, regulatory scrutiny, payer gatekeeping, and most importantly the uncompromising standard that “good enough” must keep improving because patients’ lives are at stake.

In the last decade, that tension has sharpened into something that increasingly resembles a barbell.

‍

The under-appreciated middle lane in pharma product development

On one end sits the generic industry - indispensable, efficient, and fiercely competitive. Generics deliver enormous public-health value; in the U.S., they account for roughly 90% of prescriptions filled while representing a much smaller share of overall prescription spending. But when multiple competitors enter, the economics can turn punishing - steep price erosion, thin margins, and limited room for durable differentiation.

On the other end sits frontier innovation - new molecular entities, advanced modalities, and high-complexity biologics. This is where the industry’s most dramatic breakthroughs are born. It is also where the operational burden has grown steadily - the long-run pattern of declining R&D efficiency - often described as “Eroom’s Law” - has been discussed extensively, and estimates of R&D cost span a wide range depending on methodology and therapeutic area.

Between these two poles lies a space that is often underappreciated and - when approached with rigor - surprisingly fertile - the “middle lane,” where approved medicines can be reimagined to deliver better clinical utility, better real-world usability, and broader patient impact, without taking on the full risk profile of discovering a new drug from scratch.

At Revio, we believe the middle lane is not a compromise. It is a strategy and it is the foundation of our vision, mission, and objectives.

‍

The middle lane exists because many medicines are still “unfinished”

One of the quieter truths of drug development is that first approval is rarely the final form of a medicine.

Innovators are often in a race against time - to reach patients sooner, to manage burn rates, to stay ahead in competitive landscapes, and to secure the first label that makes the product viable. That urgency is understandable - and in many cases life saving. But it also means early versions of drugs are frequently optimized for approval feasibility rather than maximal patient utility on day one.

Later, lifecycle improvements may happen - but not consistently. Incentives shift. Large organizations often prefer allocating capital and attention to the next major growth engine rather than revisiting an older asset unless there turn is obvious and immediate. The result is familiar to clinicians and patients alike - medicines that are scientifically validated yet remain suboptimal in ways that matter deeply in real life - routes of administration that limit adherence, formulations that are not designed for pediatrics, dosing that is inconvenient or error-prone, or indications that were never pursued despite credible biology.

The middle lane matters, since its where disciplined repurposing and disciplined reformulation can create value that is not cosmetic, but clinically and economically meaningful.

‍

Why this matters for patients, providers, and payers

The middle lane is sometimes described in financial terms - faster timelines, lower risk, better probability of success. Those are real advantages. But the deeper reason it matters is that the benefits extend well beyond the manufacturer.

• Patients rarely experience medicines as molecules. They experience them as routines, burdens, trade-offs, and lived reality. Thoughtful product design can translate into fewer missed doses, fewer avoidable side effects driven by exposure variability, and better access to therapies that might otherwise remain “theoretically useful” but practically hard to use.

• Providers want therapies that are both credible and workable - easy to prescribe, easy to explain, and predictable in real practice. Better dosing accuracy, more practical routes, and simpler administration reduce friction in care delivery and can reduce avoidable errors.

• Payers and health systems increasingly fund value, not novelty. A therapy that improves adherence, reduces downstream complications, or avoids escalation to higher-cost care settings can create system-level savings - provided the value is credible and measurable.

At Revio, the stakeholder lens is not a footer on a slide. It is a filter we use early, when we decide what to build and how to build it.

‍

Repurposing - Expanding impact with a credible moat

Repurposing is sometimes misunderstood. Done casually, it can resemble off-label use - informal, inconsistent, and difficult for payers to evaluate or fund responsibly. Done properly, it is something very different - a deliberate, evidence - driven program to earn a new label in a population where patients need better options - and where the underlying pharmacology is already known enough to reduce certain categories of uncertainty.

When repurposing is executed with scientific discipline, it creates a rare convergence of benefits:

• Patients gain access to a new therapeutic option in an area of unmet need, often on timelines that can be meaningfully shorter than de novo discovery.

• Providers move from anecdotal, heterogeneous off-label use to a more standardized approach with clearer dosing guidance, safety management, and evidence-anchored expectations.

• Payers gain something they can evaluate and fund responsibly - a labeled therapy, supported by a structured evidence package, rather than inconsistent real-world practice.

Just as important, when repurposing is paired with a thoughtful product strategy - appropriate formulation, patient-centric design, defensible differentiation, and a clear regulatory plan - it can create both stakeholder value and a durable moat, anchored in differentiated product architecture and a new evidence package.

Repurposing has repeatedly moved the needle in real-world care. Sildenafil, for example, was approved as Revatio for pulmonary arterial hypertension. Thalidomide’s re-emergence as Thalomid in multiple myeloma, and bupropion’s approval as Zyban for smoking cessation, are further reminders that validated pharmacology can be redirected to major clinical needs when evidence is built rigorously and the product is positioned responsibly.

‍

Reformulation - Designing medicines around real-world care

If repurposing answers the question “Who else could this medicine help?”, reformulation answers an equally important one - “How should this medicine be delivered so it can reliably help in the real world?”

Many medicines that are clinically effective still leave patients and providers wrestling with practical constraints - tolerability issues driven by peaks and troughs, inconvenient dosing schedules, difficulty in pediatric administration, or routes that don’t fit the realities of chronic disease management. Reformulation is where we convert a proven molecule into a product that works better in practice.

For patients and providers, the benefits can be very concrete:

• Improved adherence through simpler routines.

• Improved dosing accuracy (particularly when mg/kg dosing or titration matters).

• Reduced administration burden and errors.

• In some cases, improved exposure profiles that translate into better tolerability or efficacy.

For payers and health systems, well-designed reformulations can reduce avoidable downstream costs - especially when they meaningfully improve adherence or reduce complications.

Reformulation and delivery re-architecture have produced meaningful stakeholder benefit. In public health emergencies, converting an injectable into a community-ready format can be transformative - FDA reviews for Narcan(naloxone) nasal spray and Evzio (naloxone) auto-injector describe programs designed to enable practical, rapid administration by lay responders. In chronic care, drug-device combinations such as Otrexup (methotrexate) have enabled consistent self-administration of established therapies. And even “simple” dosage-form changes can address real gaps - for example, Qbrelis, alisinopril oral solution, created an FDA-approved option where many patients previously relied on extemporaneous compounding.

‍

The regulatory foundation is real- 505(b)(2), hybrid pathways, and proven precedent

The middle lane is not only scientifically attractive - it is also practical because it is supported by established regulatory frameworks.

In the U.S., the FDA’s 505(b)(2) NDA pathway allows a sponsor to rely in part on existing evidence - such as published literature and prior FDA findings for a reference product - while generating additional data as needed to support differences in the proposed product.

In Europe, generic and hybrid application pathways similarly recognize that when a product differs meaningfully from the reference medicine - through formulation, strength, route, or other differences - a hybrid approach may be appropriate, with supporting studies tailored to the change.

These pathways have produced differentiated products that are clinically meaningful and scalable. FDA documentation for Suboxone sublingual film, for example, reflects reliance on a 505(b)(2) reference for an alternative dosage form; the product became widely used in opioid use disorder treatment and helped broaden access to medication-assisted therapy.

Revio’s strategy - Four reinforcing legs

Revio is building a next-generation specialty pharma model designed specifically for the middle lane. Our strategy rests on four reinforcing legs that, taken together, position us to execute effectively while managing the inherent uncertainties of pharmaceutical development.

1)    A balanced portfolio across repurposing and reformulation

We deliberately blend programs that expand indications with programs that upgrade product design. The balance allows us to pursue near- and mid-term value creation while also building a pipeline of higher-differentiation assets where product architecture, execution, and evidence become durable moats.

2)    A consistent focus on high unmet need and stakeholder value

We do not choose programs simply because a regulatory pathway exists. We choose programs where patient and care-delivery value is clear enough to earn adoption and reimbursement - because in the end, that is what makes a product sustainable.

3)    De-risking through early, integrated partnerships

Middle-lane innovation often fails when development is treated as a sequential relay and key partners are brought in after critical decisions are locked. Our approach is to integrate early - scientific collaborators, development experts, and supply-chain partners - so feasibility, manufacturability, and scale a redesigned in, not patched in later. For select high-value programs, we may use partnership structures such as SPVs to align incentives and governance.

4)    rethinkTx ^™ as an “exoskeleton” that amplifies how we build

We are building rethink Tx^™, our AI-native platform for new product ideation and development planning. The purpose is simple - the middle lane is full of opportunity, but opportunity without a system quickly becomes noise. Many industries have a widely adopted “system of record” that standardizes complex workflows - manufacturing and enterprise operations, for example, were transformed by platforms like SAP, which created a common backbone for planning, execution, and accountability. Portfolio planning and new product ideation in pharma has never had a true equivalent. rethink Tx^™ is our attempt to build that missing layer, connecting science, regulatory feasibility, development design, and commercial logic into a coherent workflow - so we can execute our mission more systematically and at scale.

‍

Why the model works - Reducing downside while preserving defensibility

The middle-lane approach has a distinctive advantage - it can be engineered to reduce risk while still building durable moats.

Starting from proven molecules can reduce some unknowns relative to de novo discovery - particularly around baseline pharmacology and prior human exposure. Established pathways like 505(b)(2) and EU hybrid approaches can enable development programs that are more tailored to what is genuinely new in the product, rather than recreating an entire evidence base from scratch.

At the same time, the strongest middle-lane assets are not “me-too generics.” They are engineered products with a reason to exist; differentiated product architecture, a credible evidence package, and a value proposition that matters to patients, providers, and payers. The moat may come from formulation or device integration, from new clinical data in a new indication, or from the totality of a development package that would be difficult and time-consuming to replicate.

Done properly, we can create a portfolio that can be both execution-realistic and defensible - a combination that is genuinely difficult to achieve at either extreme of the pharmaceutical barbell.

‍

Looking ahead - Why the middle lane will matter even more

Generic pressure is unlikely to ease, and frontier innovation will remain essential - but not every patient need can wait for a decade-long, high-attrition path. In that context, we believe 505(b)(2) and hybrid strategies - executed with rigor- will play an increasingly important role in improving therapies, expanding access, and delivering value that holds up in outcomes.

‍

Join us and follow along

This is the first post in a series that will unpack how we think about reimagining approved medicines - the logic, the pathways, the partnerships, and the role of AI in building better portfolios and better products.

Over the coming weeks, we’ll share our perspective on why 505(b)(2) matters, how we partner, why drug-device combinations are becoming central, and how translational biology and PK/PD rigor can make the difference between an interesting idea and an approvable product.

If you are a potential collaborator - scientific, clinical, regulatory, manufacturing, or strategic - we would love to explore how we can build together. And if you’re simply curious about the future of the middle lane, we invite you to follow along as we continue to publish, refine our thinking, and share what we are learning on the journey.

Revio is an AI-native specialty pharma reimagining proven drugs into faster, lower-risk innovations - so more patients can benefit from medicines we already know can work.

‍

References

1. Association for Accessible Medicines (AAM). 2025 U.S. Generic & Biosimilar Medicines Savings Report.

2. IQVIA Institute. Price Declines after Branded Medicines Lose Exclusivity in the U.S.

3. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11(3):191–200.doi:10.1038/nrd3681.

4. Sertkaya A, et al. Costs of Drug Development and Research and Development Expenditures in the U.S., 2008–2019. JAMA Network Open. 2024.

5. U.S. Food and Drug Administration (FDA). Guidance for Industry: Applications Covered by Section 505(b)(2).

6. European Medicines Agency (EMA). Generic and hybrid applications.

7. FDA. Suboxone (buprenorphine and naloxone) sublingual film – NDA 022410approval/review documents.

8. FDA. Narcan (naloxone hydrochloride) nasal spray – NDA 208411 review/approval documents.

9. FDA. Evzio (naloxone) auto-injector – NDA 205787 review/approval documents.

10.  FDA. Otrexup (methotrexate) auto-injector – NDA 204824 review/approval documents.

11.  FDA. Qbrelis (lisinopril) oral solution – NDA 208401 review/approval documents.

12.  FDA. Revatio (sildenafil) – NDA 021845 approval/labeling documents.

13.  FDA. Thalomid (thalidomide) – NDA 021430 approval/labeling documents.

14.  FDA. Zyban (bupropion SR) – NDA 020711 approval/review documents.

15.  FDA. Determining Whether to Submit an ANDA or a 505(b)(2) Application.

‍

About the Author

Sreevatsa Natarajan | Co-Founder, Chief Executive Officer

Vatsa has over 25 years of experience in pharma product development and commercialization with contribution to 15 NDAs, 25+ INDs, and several marketed therapies. A serial entrepreneur and seasoned R&D leader, he brings deep expertise across global organizations including Vertex, PPD, Glenmark, DRL Aurigene, Sapien (a JV with Apollo Hospitals), and Rhizen. Vatsa excels at converting complex scientific ideas into viable businesses by building high-performance teams.